BridgeMD
New treatment option for Preeclampsia Postpartum
Official title Aspirin for Postpartum Patients With Preeclampsia
ClinicalTrials.gov ID: NCT05924971
What this study is testing
What is Aspirin 81Mg Ec Tab?
Aspirin 81Mg Ec Tab is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for preeclampsia postpartum.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The purpose of this research study is to evaluate the effect of low-dose aspirin on recovery from severe preeclampsia (a high blood pressure disorder of pregnancy) among women who have given birth. We hypothesize that taking aspirin for the first week after giving birth will enhance recovery from preeclampsia by decreasing the levels of a protein called soluble fms-like tyrosine kinase (sFlt-1), which is thought to be a main contributor to the development of preeclampsia, and speeding up return to a normal blood pressure.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older, women only
You may be able to join if
- Preeclampsia with severe features diagnosed during delivery admission, as defined by ACOG criteria.
- Pre- and postnatal care provided by the Long Beach Memorial Ob/Gyn resident or Maternal-Fetal Medicine clinic.
You likely can't join if
- Patient age \<18 years old
- Non-English or Non-Spanish speaking
- Chronic hypertension diagnosed before 20 weeks' gestation
- Known allergy, prior adverse reaction, or any medical condition in which aspirin is contraindicated (nasal polyps, gastric or duodenal ulcers...
- Aspirin prescribed postpartum for any other medical condition
- Bleeding disorder
See the full eligibility criteria
- Preeclampsia with severe features diagnosed during delivery admission, as defined by ACOG criteria.
- Pre- and postnatal care provided by the Long Beach Memorial Ob/Gyn resident or Maternal-Fetal Medicine clinic.
- Patient age \<18 years old
- Non-English or Non-Spanish speaking
- Chronic hypertension diagnosed before 20 weeks' gestation
- Known allergy, prior adverse reaction, or any medical condition in which aspirin is contraindicated (nasal polyps, gastric or duodenal ulcers, history of gastrointestinal bleeding, severe hepatic dysfunction)
- Aspirin prescribed postpartum for any other medical condition
- Bleeding disorder
- Breastfeeding an infant with thrombocytopenia
The study team makes the final eligibility decision.
Where it's taking place
- Long Beach, California, United States
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Long Beach, California, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.